Drug-Drug Interactions and Their Association With Quality of Life in Patients With Hypertension

被引:0
作者
Gurel, Nermin [1 ]
Uresin, Yagiz [2 ]
Sen, Selcuk [2 ]
机构
[1] Mehmet Akif Ersoy Thorac & Cardiovasc Surg Trainin, Good Clin Practice & Res Ctr, Pharmacol & Therapeut, Istanbul, Turkiye
[2] Istanbul Univ, Istanbul Fac Med, Div Clin Pharmacol, Med Pharmacol, Istanbul, Turkiye
关键词
body mass index; age; quality of life; drug interaction; antihypertensive; hypertension;
D O I
10.7759/cureus.56526
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction This study aimed to evaluate drug -drug interactions (DDIs) and their association with the quality of life in patients with hypertension. Materials and methods This cross-sectional study included 123 patients with hypertension. DDIs were evaluated using the Medscape Drug Interaction Checker Database (Medscape, New York, NY). The EuroQol-5D (EQ-5D) Quality of Life Scale was used for each patient. Results The overall blood pressure control rate (systolic/diastolic blood pressure levels, <140/90 mmHg) was 43% (53/123). The age of the patients with uncontrolled hypertension was higher than the patients with controlled hypertension (63.67 +/- 11.00 vs. 58.42 +/- 10.07 years; p = 0.007). The number of DDIs showed significant correlations, positively with age (r = 0.303, p = 0.001), total number of drugs (r = 0.784, p < 0.001), number of antihypertensive drugs (r = 0.640, p < 0.001), and body mass index (BMI) (r = 0.321, p < 0.001) and inversely with EQ-5D index score (r = -0.247, p = 0.006). The EQ-5D index and visual analog score were inversely correlated with age and BMI. Additional significant linear correlations between age and the total number of drugs, age and number of the antihypertensive drugs, the number of antihypertensive drugs and BMI, and the number of total drugs and BMI were detected. Of a total of 511 identified DDIs, 14 interactions in 12 patients were considered serious, 402 interactions in 82 patients were considered significant, and 95 interactions in 39 patients were considered minor. Conclusions This study supports that DDIs have important associations with antihypertensive treatment and the quality of life of patients. Higher age and BMI values were associated with a higher risk of DDIs and lower quality of life in patients with hypertension.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer
    Fogli, Stefano
    Gianfilippo, Giulia
    Cucchiara, Federico
    Re, Marzia Del
    Valerio, Laura
    Elisei, Rossella
    Danesi, Romano
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 163
  • [32] Assessment of potential drug-drug interactions with a prescription claims database
    Malone, DC
    Hutchins, DS
    Haupert, H
    Hansten, P
    Duncan, B
    Van Bergen, RC
    Solomon, SL
    Lipton, RB
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (19) : 1983 - 1991
  • [33] Artificial Intelligence and Data Mining for the Pharmacovigilance of Drug-Drug Interactions
    Hauben, Manfred
    CLINICAL THERAPEUTICS, 2023, 45 (02) : 117 - 133
  • [34] Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions
    Hollywood, Paul
    MacCann, Rachel
    Lorigan, David
    de Barra, Eoghan
    McConkey, Samuel
    IRISH JOURNAL OF MEDICAL SCIENCE, 2020, 189 (02) : 693 - 699
  • [35] The prevalence of potential drug-drug interactions in adults with intellectual disability
    McMahon, M.
    Hatton, C.
    Bowring, D. L.
    Hardy, C.
    Preston, N. J.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2021, 65 (10) : 930 - 940
  • [36] Mining clinical text for signals of adverse drug-drug interactions
    Iyer, Srinivasan V.
    Harpaz, Rave
    LePendu, Paea
    Bauer-Mehren, Anna
    Shah, Nigam H.
    JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2014, 21 (02) : 353 - 362
  • [37] A 3-DIMENSIONAL MODEL TO ANALYZE DRUG-DRUG INTERACTIONS
    PRICHARD, MN
    SHIPMAN, C
    ANTIVIRAL RESEARCH, 1990, 14 (4-5) : 181 - 206
  • [38] Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review
    Boudou-Rouquette, Pascaline
    Tlemsani, Camille
    Blanchet, Benoit
    Huillard, Olivier
    Jouinot, Anne
    Arrondeau, Jennifer
    Thomas-Schoemann, Audrey
    Vidal, Michel
    Alexandre, Jerome
    Goldwasser, Francois
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (12) : 1433 - 1444
  • [39] Clinical Pertinence and Determinants of Potential Drug-Drug Interactions in Chronic Kidney Disease Patients: A Cross-sectional Study
    Khanna, Janvi
    Kumar, Siddharth
    Mehta, Sudhir
    Chaudhary, Jasmine
    Jain, Akash
    JOURNAL OF PHARMACY TECHNOLOGY, 2024, 40 (03) : 142 - 151
  • [40] Evaluation of Potential Drug-Drug Interactions among Patients of the Nephrology and Kidney Transplant Wards of a Major Teaching Hospital in Iran
    Khamas, Shahriyar Shahbazi
    Lebadi, Mohammadkazem
    Ashouri, Asieh
    Mokhtari, Gholamreza
    Jafari, Atefeh
    JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, 2021, 33 (38B) : 66 - 78